In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Follow-on offering nets Oncolytics $Cdn3.45mm

Executive Summary

Oncolytics Biotech (developing oncolytic virsues as cancer therapies) netted $Cdn3.45mm ($2.8mm) through a follow-on public offering of 2.5mm common shares at $Cdn1.50 each. Investors also received three-year warrants to purchase 2.5mm shares at $Cdn1.80 apiece.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies